Ocugen and Bharat Biotech to Co-Develop COVAXIN™, a Whole-Virion Inactivated COVID-19 …,

The vaccine candidate is currently part of a Phase 3 clinical trial in India involving 26,000 volunteers. Per the LOI, Ocugen will have US rights to the …, The vaccine candidate is currently part of a Phase 3 clinical trial in India involving 26,000 volunteers. Per the LOI, Ocugen will have US rights to the …, Read More

Scroll to Top